Please complete the CAPTCHA to continue
@cabalettabio.com
✓
1 phone found area 201
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Matthew Deangelis is listed as Associate Director, Clinical Operations at Immix Biopharma (Nasdaq: IMMX), based in Belmar, New Jersey, United States. AeroLeads shows a work email signal at cabalettabio.com, phone signal with area code 201, and a matched LinkedIn profile for Matthew Deangelis.
Matthew Deangelis previously worked as Associate Director Clinical Operations at Immix Biopharma (Nasdaq: Immx) and Associate Director, Clinical Operations at Cabaletta Bio. Matthew Deangelis holds Ba, Psychology from Rutgers University.
This section adds company-level context without repeating Matthew Deangelis's masked contact details.
AeroLeads found 1 current-domain work email signal for Matthew Deangelis. Compare company email patterns before reaching out.
I am a Clinical Development professional with 20+ years of industry experience in end-to-end clinical trial design, execution, interpretation and reporting. My therapeutic area exposure includes cancer immunotherapy, autologous cell therapy, autoimmune disease, neurology, and anesthesia & critical care.Please note: Any posts, comments, or "likes" on LinkedIn may represent my own views, but are not necessarily those of my employer.
Listed skills include Clinical Trials, Clinical Development, Ctms, Cro, and 17 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Los Angeles, CA, US
Associate Director, Clinical Operations in Cell Therapy (CAR-T) for Immix Bio. Immix Biopharma, Inc. (“ImmixBio”) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering personalized immunotherapies for cancer and rare diseases. Our subsidiary Nexcella, Inc.’s lead cell therapy product, NXC-201, is a BCMA-targeted investigational chimeric.
Philadelphia, Pennsylvania, US
Clinical development of autologous engineered T cell (CAART) products that target B cell-mediated autoimmune diseases. Lead the phase 1 program for MuSK-CAART in MuSK-associated myasthenia gravis (MG).
Edison, NJ, US
Clinical development of a portfolio of small molecule TLR 7/8 agonist, including Phase I/II dose escalation and dose expansion studies (BDB001).
Edison, NJ, US
Clinical development of the TLR 7/8 agonist portfolio in the US and Europe, including Phase II program for BDB001 monotherapy in anti-PD-(L)1 refractory tumors.
Rahway, New Jersey, US
Sr. Study Manager in a hybrid Study Manager / Clinical Scientist role in a multi- study international trial program for Bridion (sugammadex), in Anesthesia & Critical Care. I was responsible for study operations and vendor management related to NMTM (Neuromuscular Transmission Monitoring) data collection, monitoring and interpretation. NMTM data are a.
Rahway, New Jersey, US
Sr. Study Manager Tasks and responsibilities: Operational planning, feasibility, and execution of clinical protocols.Accomplishments: lead the program team through early study planning, development and startup execution activities; transitioned to the clinical trial team (CTT) lead for a pediatric efficacy/safety/PK study in Sugammadex (timeline.
Rahway, New Jersey, US
Design and conduct of clinical studies in Anesthesia & Critical Care, including: protocol development, protocol level planning, operational feasibility, aggregate safety reporting, clinical study reports, investigator brochures, manuscripts, regulatory agency update reports, investigator outreach and advisory board development, safety and medical.
Rahway, New Jersey, US
Phase IIb Efficacy and Population PK study in Migraine ( MK-1602 / ubrogepant ) Phase IIIb/V study in Anesthesia / Neuromuscular BlockadePhase IIIb Emerging Markets / Local Registration study (South Korea) in Anesthesia / Neuromuscular Blockade
Rahway, New Jersey, US
Senior Clinical Trial Associate in Anesthesia & Analgesia, US Phase IIIb of SugammadexTrainer / SME / Medical Device Support for the Anesthesia Franchise: TOF-Watch device (measures neuromuscular function)
St. Gallen, Switzerland, CH
Technical PM of Data Management CRO, Phase III CellCept in SLE (Systemic Lupus Erythematous)
Quick answers generated from the profile data available on this page.
Matthew Deangelis works for Immix Biopharma (Nasdaq: IMMX).
Matthew Deangelis is listed as Associate Director, Clinical Operations at Immix Biopharma (Nasdaq: IMMX).
AeroLeads has found 1 work email signal at @cabalettabio.com for Matthew Deangelis at Immix Biopharma (Nasdaq: IMMX).
AeroLeads has found 1 phone signal(s) with area code 201 for Matthew Deangelis at Immix Biopharma (Nasdaq: IMMX).
Matthew Deangelis is based in Belmar, New Jersey, United States while working with Immix Biopharma (Nasdaq: IMMX).
Matthew Deangelis has worked for Immix Biopharma (Nasdaq: Immx), Cabaletta Bio, Seven And Eight Biopharmaceuticals Inc., Merck, and Vifor Pharma.
You can use AeroLeads to view verified contact signals for Matthew Deangelis at Immix Biopharma (Nasdaq: IMMX), including work email, phone, and LinkedIn data when available.
Matthew Deangelis holds Ba, Psychology from Rutgers University.
Matthew Deangelis is listed with skills including Clinical Trials, Clinical Development, Ctms, Cro, Clinical Research, Neurology, Clinical Study Design, and Training.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts